The neurodegenerative disease will grow globally by 112% in 2050 compared to 2021, according to the latest estimates ...

25 million people across the world will be living with a debilitating brain condition by 2050, scientists have warned ...

The uptick is expected to be driven largely by population growth and ageing, with developing countries seeing the greatest ...

By 2050, there will be 25.2 million people living with Parkinson's disease worldwide (a 112% increase from 2021), largely due to population ageing, suggests a modelling study published by The BMJ ...

More advanced methods may enable better modelling Parkinson’s disease is a considerable health problem owing to its high and rising global prevalence, its progressively degenerative nature, and its ...

Parkinson’s disease is set to rise dramatically, with cases expected to more than double by 2050, largely due to an aging ...

By 2050, there will be 25.2 million people living with Parkinson's disease worldwide (a 112% increase from 2021), largely due ...

OVER 25 million people across the world will be living with a debilitating brain condition by 2050, scientists have warned.

Jazz Pharmaceuticals plc is buying Chimerix Inc. for $8.55 a share, bringing the deal in at about $935 million. Jazz expands its cancer pipeline with the new acquisition’s lead candidate, dordaviprone ...

Incidence of Parkinson disease significantly lower with early CPAP treatment, but no reduction seen with late CPAP treatment ...

Groundbreaking research that has led to the development of a wrist device to help control tics in people with Tourette ...

Zandy Forbes’ biotech company MeiraGTx has developed targeted gene therapy methods to treat more than just genetic disorders.